Overcoming physician barriers to increase DTx adoption

Overcoming physician barriers to increase DTx adoption

How to get physicians onboard for wider DTx adoption and use

What role are healthcare professionals playing in the relatively slow uptake of DTx? While physicians are positive about the value of DTx, they remain cautious about the broader impacts. Concerns about increased administration, integration into clinical workflows, the risks associated with DTx use, and the need for better patient support and physician education are barriers which must be overcome. What strategies can DTx manufacturers employ to get all physicians onside?

Companies

Roche, Sanofi, Biogen, Google, Facebook, Novo Nordisk, Fitbit, Noom, Livongo, Proteus Digital Health, Welldoc, Omada Health, Apple, Dario, Amwell, Pear Therapeutics, Walmart, Boehringer Ingelheim, Big Health, Biofourmis, Chugai, Click Therapeutics, CVS, Happify, Ironwood Pharmaceuticals, Kaia, Lark, NightWare, One Drop, Orexo, Teladoc, Shionogi, Silver Cloud, Voluntis, Welthys Therapeutics, Express Scripts, Orcha, United Healthcare, Cognoa, Abbott, BehaVR, Freespira, Natural Cycles, Optum, Walgreens, GAIA AG, Mahana Therapeutics, mynoise GmbH, Rehappy GmbH, Theranica, Vivira Health Lab, Motto, e-therapeutics, Otsuka Pharmaceutical, Akili Interactive, BrightView Health, Selfapy GmbH, Sympatient GmbH, Crea, GoGoMeds, Livia Health, mementor DE GmbH, Miami, Peach Health Asia, Truepill, Twill, Virta Health, Youturn, Xealth, Zuellig Pharma